Cureus . Johnson and Johnson COVID-19 Vaccination Triggering Pheochromocytoma Multisystem Crisis

[tetano]

Cureus


. 2021 Sep 22;13(9):e18196.
doi: 10.7759/cureus.18196. eCollection 2021 Sep.
Johnson and Johnson COVID-19 Vaccination Triggering Pheochromocytoma Multisystem Crisis


Nahel Haji Jr ¹ , Sofiah Ali ¹ , Emad A Wahashi ¹ , Mahrukh Khalid ¹ , Kalyana Ramamurthi ²



Affiliations

• PMID: 34707965
• PMCID: PMC8536310
• DOI: 10.7759/cureus.18196

Abstract

Pheochromocytomas are rare tumors that may have variable presentations. The presentation may depend on the type of catecholamine secreted, whether there is a paraneoplastic syndrome or not, or some other factor which may not be well understood. One rare presentation is a pheochromocytoma multisystem crisis. Many of these tumors are asymptomatic and found incidentally, but some can be triggered after being previously dormant. In this case report, we describe the first case of pheochromocytoma multisystem crisis triggered by the Johnson and Johnson (J&J) coronavirus disease 2019 (COVID-19) vaccine. We describe a case of a 63-year-old Caucasian male who presented with intractable nausea, vomiting, dyspnea, watery diarrhea, chills, sweats, and heavy chest pain starting one day status post J&J COVID-19 vaccination. He had no symptoms prior to this and no significant past medical history besides daily marijuana use. During his hospital stay, he had persistent high fevers, respiratory failure, cardiogenic shock, cardiomyopathy, and labile blood pressure measurements. After a retroperitoneal ultrasound, he was found to have a 7 cm mass in the right adrenal gland with elevated chromogranin A, urine vanillylmandelic acid (VMA), and urinary 24-hour metanephrines to confirm the diagnosis of a pheochromocytoma.

Keywords: adverse event; j&j covid-19 vaccine; pheochromocytoma multisystem crisis; rare; triggered.